Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarctionThis article is one of a selection of papers published in the special issue Bridging the Gap: Where Progress in Cardiovascular and Neurophysiologic Research Meet.
Abstract:To investigate the mechanisms underlying the depressed sarcolemmal (SL) Na(+)-K(+)-ATPase activity in congestive heart failure (CHF), different isoforms and gene expression of Na(+)-K(+)-ATPase were examined in the failing left ventricle (LV) at 8 weeks after myocardial infarction (MI). In view of the increased activity of renin-angiotensin system (RAS) in CHF, these parameters were also studied after 5 weeks of treatment with enalapril (10 mg x kg-1 x day-1), an angiotensin-converting enzyme inhibitor, and lo… Show more
“…Similarly, antihypertensive agents (i.e. losartan and enalapril) attenuated the decreased activity of sarcolemmal Na C /K C -ATPase in the failing heart of rats after myocardial infarction (Guo et al 2008). Further studies are needed to investigate the impact of such CV risk-reducing drugs on Na C /K CATPase function.…”
“…Similarly, antihypertensive agents (i.e. losartan and enalapril) attenuated the decreased activity of sarcolemmal Na C /K C -ATPase in the failing heart of rats after myocardial infarction (Guo et al 2008). Further studies are needed to investigate the impact of such CV risk-reducing drugs on Na C /K CATPase function.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.